First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

BACKGROUND: MDM2/MDMX proteins are frequently elevated in hormone receptor-positive (ER+) breast cancer. We sought to determine the antitumor efficacy of the combination of ALRN-6924, a dual inhibitor of MDM2/MDMX, with chemotherapy in ER+ breast cancer models. METHODS: Three hundred two cell lines...

Descripción completa

Detalles Bibliográficos
Autores principales: Pairawan, Seyed, Zhao, Ming, Yuca, Erkan, Annis, Allen, Evans, Kurt, Sutton, David, Carvajal, Luis, Ren, Jian-Guo, Santiago, Solimar, Guerlavais, Vincent, Akcakanat, Argun, Tapia, Coya, Yang, Fei, Bose, Priya Subash Chandra, Zheng, Xiaofeng, Dumbrava, Ecaterina Ileana, Aivado, Manuel, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934277/
https://www.ncbi.nlm.nih.gov/pubmed/33663585
http://dx.doi.org/10.1186/s13058-021-01406-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934277/
https://www.ncbi.nlm.nih.gov/pubmed/33663585
http://dx.doi.org/10.1186/s13058-021-01406-x

Ejemplares similares